Immunotherapy in the initial treatment of newly diagnosed cancer patients: Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer

Ya Chen Tina Shih, Linda S. Elting, Alexandre L. Pavluck, Andrew Stewart, Michael Halpern

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We analyzed the utilization trend for immunotherapy as initial treatment in the United States and estimated the cost impact of three cancers for which the majority of newly approved immunotherapies were indicated: non-Hodgkin's lymphoma (NHL), metastatic breast cancer (MBC), and metastatic colorectal cancer (MCRC). Utilization was highly concentrated, with four cancers accounting for 7080 of use. On the basis of the pattern in 2004 (22.9 NHL, 3.2 MCRC, and 3.3 MBC), immunotherapy was associated with $285, $73, and $12 million cost increase for NHL, MCRC, and MBC, respectively. Costs for these cancers would have exceeded $1.82 billion had 50 of eligible patients received immunotherapy.

Original languageEnglish (US)
Pages (from-to)46-53
Number of pages8
JournalCancer Investigation
Volume28
Issue number1
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Immunotherapy
Breast Neoplasms
Costs and Cost Analysis
Colorectal Neoplasms
Neoplasms
Therapeutics

Keywords

  • Health sciences research
  • Monoclonal antibodies
  • Outcomes research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunotherapy in the initial treatment of newly diagnosed cancer patients : Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer. / Shih, Ya Chen Tina; Elting, Linda S.; Pavluck, Alexandre L.; Stewart, Andrew; Halpern, Michael.

In: Cancer Investigation, Vol. 28, No. 1, 2010, p. 46-53.

Research output: Contribution to journalArticle

@article{ca18a968564941d38fcb1a8e757ba012,
title = "Immunotherapy in the initial treatment of newly diagnosed cancer patients: Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer",
abstract = "We analyzed the utilization trend for immunotherapy as initial treatment in the United States and estimated the cost impact of three cancers for which the majority of newly approved immunotherapies were indicated: non-Hodgkin's lymphoma (NHL), metastatic breast cancer (MBC), and metastatic colorectal cancer (MCRC). Utilization was highly concentrated, with four cancers accounting for 7080 of use. On the basis of the pattern in 2004 (22.9 NHL, 3.2 MCRC, and 3.3 MBC), immunotherapy was associated with $285, $73, and $12 million cost increase for NHL, MCRC, and MBC, respectively. Costs for these cancers would have exceeded $1.82 billion had 50 of eligible patients received immunotherapy.",
keywords = "Health sciences research, Monoclonal antibodies, Outcomes research",
author = "Shih, {Ya Chen Tina} and Elting, {Linda S.} and Pavluck, {Alexandre L.} and Andrew Stewart and Michael Halpern",
year = "2010",
doi = "10.3109/07357900902783187",
language = "English (US)",
volume = "28",
pages = "46--53",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Immunotherapy in the initial treatment of newly diagnosed cancer patients

T2 - Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer

AU - Shih, Ya Chen Tina

AU - Elting, Linda S.

AU - Pavluck, Alexandre L.

AU - Stewart, Andrew

AU - Halpern, Michael

PY - 2010

Y1 - 2010

N2 - We analyzed the utilization trend for immunotherapy as initial treatment in the United States and estimated the cost impact of three cancers for which the majority of newly approved immunotherapies were indicated: non-Hodgkin's lymphoma (NHL), metastatic breast cancer (MBC), and metastatic colorectal cancer (MCRC). Utilization was highly concentrated, with four cancers accounting for 7080 of use. On the basis of the pattern in 2004 (22.9 NHL, 3.2 MCRC, and 3.3 MBC), immunotherapy was associated with $285, $73, and $12 million cost increase for NHL, MCRC, and MBC, respectively. Costs for these cancers would have exceeded $1.82 billion had 50 of eligible patients received immunotherapy.

AB - We analyzed the utilization trend for immunotherapy as initial treatment in the United States and estimated the cost impact of three cancers for which the majority of newly approved immunotherapies were indicated: non-Hodgkin's lymphoma (NHL), metastatic breast cancer (MBC), and metastatic colorectal cancer (MCRC). Utilization was highly concentrated, with four cancers accounting for 7080 of use. On the basis of the pattern in 2004 (22.9 NHL, 3.2 MCRC, and 3.3 MBC), immunotherapy was associated with $285, $73, and $12 million cost increase for NHL, MCRC, and MBC, respectively. Costs for these cancers would have exceeded $1.82 billion had 50 of eligible patients received immunotherapy.

KW - Health sciences research

KW - Monoclonal antibodies

KW - Outcomes research

UR - http://www.scopus.com/inward/record.url?scp=72449132792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449132792&partnerID=8YFLogxK

U2 - 10.3109/07357900902783187

DO - 10.3109/07357900902783187

M3 - Article

C2 - 19995227

AN - SCOPUS:72449132792

VL - 28

SP - 46

EP - 53

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 1

ER -